Tc99m-tilmanocept

DRUG4 trials

Sponsors

Navidea Biopharmaceuticals

Conditions

Arthritis, RheumatoidHIV InfectionsKaposi SarcomaNASH - Nonalcoholic SteatohepatitisNonalcoholic SteatohepatitisRheumatoid Arthritis

Phase 1

Evaluating Safety of Escalating Doses of Tilmanocept by IV Injection and SPECT Imaging in Subjects With and Without RA

CompletedNCT02865434

Navidea BiopharmaceuticalsArthritis, Rheumatoid

Start: 2017-01-31End: 2018-06-30Updated: 2021-08-12

An Evaluation of Tc 99m Tilmanocept by Intravenous (IV) and Subcutaneous (SC) Injection in Kaposi Sarcoma (KS)

CompletedNCT03157167

Navidea BiopharmaceuticalsHIV Infections, Kaposi Sarcoma

Start: 2017-12-01End: 2020-03-30Updated: 2025-03-05

Safety Evaluation of IV Tc 99m Tilmanocept and Comparison of Imaging With Sulfur Colloid in Subjects With and Without NASH

TerminatedNCT03332940

Navidea BiopharmaceuticalsNASH - Nonalcoholic Steatohepatitis, Nonalcoholic Steatohepatitis

Start: 2017-12-06End: 2019-03-10Updated: 2024-12-24

Phase 3

Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFα Therapy Response in Moderate to Severe Active RA

TerminatedNCT05246280

Navidea BiopharmaceuticalsRheumatoid Arthritis

Start: 2022-03-02End: 2024-07-09Updated: 2025-01-23